These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 36791472)

  • 21. Commentary on ZD1839 (Iressa) in non small cell lung cancer.
    Ranson M; Thatcher N
    Lung Cancer; 2003 Apr; 40(1):77-8. PubMed ID: 12660010
    [No Abstract]   [Full Text] [Related]  

  • 22. Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.
    Cai H; Zhang L; Li N; Chen S; Zheng B; Yang J; Weng L; Liu MB
    Clin Ther; 2019 Feb; 41(2):280-290. PubMed ID: 30639208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].
    Ohashi K; Takamori M; Takahashi Y; Kawai S; Yamamoto M; Kitazono M; Murata K; Wada A
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):55-59. PubMed ID: 30765643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study.
    Hsu JC; Wei CF; Yang SC
    BMJ Open; 2019 Mar; 9(3):e022293. PubMed ID: 30878976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer.
    Yokota H; Sato K; Sakamoto S; Okuda Y; Asano M; Takeda M; Nakayama K; Miura M
    J Clin Pharm Ther; 2020 Aug; 45(4):652-659. PubMed ID: 32402096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-365a-5p suppresses gefitinib resistance in non-small-cell lung cancer through targeting PELI3.
    Li F; Li H; Li S; Lv B; Shi J; Yan H; Zhang H; He Y
    Pharmacogenomics; 2020 Jul; 21(11):771-783. PubMed ID: 32635799
    [No Abstract]   [Full Text] [Related]  

  • 27. [Iressa (gefitinib)].
    Kudoh S; Yoshimura A; Gemma A
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1079-84. PubMed ID: 12938261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
    Kakiuchi S; Yano S; Sone S
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1831-8. PubMed ID: 16223143
    [No Abstract]   [Full Text] [Related]  

  • 29. [Successful treatment of non-small cell lung cancer by gefitinib in an elderly patient with poor performance status].
    Miyoshi S; Hamada H; Ito R; Hamaguchi N; Kadowaki T; Higaki J
    Nihon Ronen Igakkai Zasshi; 2008 May; 45(3):338-42. PubMed ID: 18622121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and Design of a Randomized Phase 2 Trial of Gefitinib Plus Bevacizumab vs Gefitinib Alone in Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer: Study Protocol.
    Kitagawa C; Kada A; Saito AM; Ichinose Y; Saka H
    Kurume Med J; 2019 May; 65(2):77-81. PubMed ID: 30429415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
    Vansteenkiste J; Wauters E
    Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
    [No Abstract]   [Full Text] [Related]  

  • 32. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
    Gu ZB; Liao LM; Yao GJ; Fang M; Huang L
    Curr Probl Cancer; 2021 Oct; 45(5):100702. PubMed ID: 33454089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
    Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
    Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
    Gridelli C; Maione P; Castaldo V; Rossi A
    Br J Cancer; 2003 Nov; 89(10):1827-9. PubMed ID: 14612886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
    Dahlberg SE; Gray RJ; Johnson BE
    J Clin Oncol; 2008 Sep; 26(26):4233-5. PubMed ID: 18779608
    [No Abstract]   [Full Text] [Related]  

  • 37. Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
    Passaro A; Alesini D; Pochesci A; Cortesi E
    Anticancer Agents Med Chem; 2014 Jun; 14(5):646-50. PubMed ID: 23140355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
    Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
    Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gefitinib plus Fuzheng Kang'ai Formula () in Patients with Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation: A Randomized Controlled Trial.
    Yang XB; Chai XS; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Xiao SJ
    Chin J Integr Med; 2018 Oct; 24(10):734-740. PubMed ID: 28795387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib maintenance in stage III non-small-cell lung cancer.
    Stewart DJ
    J Clin Oncol; 2008 Oct; 26(29):4849-50; author reply 4850-1. PubMed ID: 18779595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.